PepperLedger
COMPOUND LIBRARY·SVETINORM
◈ Part of the Bioregulator Series →
Also in the Bioregulator Series
COMPOUND PROFILE · PEPPERLEDGER

Svetinorm

Khavinson et al. · Saint Petersburg Institute of Bioregulation and Gerontology
Type
Cytomax — natural peptide complex extracted from liver tissue of young calves
Class
Liver organ bioregulator · Hepatocyte gene expression regulator · Detoxification support · Anti-fibrotic hepatic · Liver aging modulator
Administration
Oral enteric-coated capsule · 2 capsules twice daily for 10 days · Twice yearly
Half-life
Short individual peptide half-lives; 4–6 month biological aftereffect characteristic of Cytomax formulations
Most studied use
Hepatic aging support · Liver detoxification maintenance · NAFLD support · Liver protection during compound protocols
Regulatory status
Not FDA-approved · Available through Russian and European suppliers · Research compound
Human evidence
Limited — Khavinson group clinical data in liver disease patients; no independent Western RCTs
Preclinical evidence
Moderate — hepatocyte gene expression normalisation, anti-fibrotic hepatic effects, detoxification enzyme support

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is Svetinorm?

Svetinorm is the liver Cytomax in the Khavinson bioregulator system — a natural peptide complex extracted from liver tissue of young calves. Its tissue target is the liver: specifically hepatocytes (the parenchymal cells that perform the liver's metabolic, detoxification, and synthetic functions) and Kupffer cells (the liver's resident macrophages). Liver-derived peptides interact selectively with chromatin in hepatocytes, activating gene expression programs for detoxification enzyme production, hepatocyte survival, regenerative capacity, and anti-inflammatory regulation.

The liver is the body's primary detoxification organ — and for PepperLedger users running multiple compound protocols, it is one of the most worked organs in the body. Every peptide, supplement, and drug is processed through the liver via Phase I (cytochrome P450 oxidation) and Phase II (conjugation) reactions. Maintaining optimal liver function is not just a longevity goal — it is a practical requirement for anyone running a complex protocol stack.

Svetinorm approaches liver health from the gene expression angle — a different and complementary mechanism to TUDCA (which works pharmacologically on bile acid composition and ER stress) and NAC (which provides the cysteine substrate for hepatic glutathione synthesis). Three different mechanisms, three different layers of liver protection.

How it works

Hepatocyte-Specific Chromatin Regulation

Liver-derived short peptides interact selectively with chromatin in hepatocytes — the principle of organ-specific bioregulation applied to the liver. The gene expression programs activated include: detoxification enzyme upregulation (CYP450 isoforms, UDP-glucuronosyltransferases, glutathione S-transferases), hepatocyte survival and anti-apoptotic signalling, regenerative pathway activation (the liver is uniquely capable of regeneration — bioregulators support this capacity), and anti-inflammatory regulation of Kupffer cell activity.

Detoxification Support

The liver processes virtually everything through Phase I oxidation (CYP450 enzymes) and Phase II conjugation reactions. Optimal expression of these enzyme systems is required for efficient detoxification. Age-related and disease-related decline in hepatic enzyme expression impairs detoxification capacity — leading to slower drug clearance, increased toxic intermediate accumulation, and reduced elimination of metabolic waste. Svetinorm's gene expression support of detoxification enzyme production addresses this aging decline directly.

Anti-Fibrotic Hepatic Effects

Liver fibrosis — accumulation of fibrous tissue replacing functional hepatocytes — is the final common pathway of most chronic liver diseases. Liver-derived peptides reduce hepatic stellate cell activation (the primary driver of liver fibrosis), reduce TGF-β1-driven fibrotic signalling in hepatic tissue, and support hepatocyte survival over fibrous replacement. The 4–6 month Cytomax aftereffect means a twice-yearly course provides year-round hepatoprotective gene expression support.

What the research shows

KHAVINSON GROUP DATA PRIMARILY · NO INDEPENDENT WESTERN RCTS
STUDYBulletin of Experimental Biology and Medicine · 2003

Liver peptide bioregulator improves hepatic function in chronic liver disease

Khavinson VKh et al.

Patients with chronic liver disease. Liver Cytomax course improved ALT, AST, bilirubin, and albumin parameters vs. controls. Reduced liver enzyme elevation and improved hepatic synthetic function. Khavinson-group observational data establishing clinical use pattern.

View on PubMed →
STUDYBulletin of Experimental Biology and Medicine · 2012

Peptide regulation of liver gene expression in aging

Khavinson VKh, Linkova NS et al.

Liver tissue models. Liver-derived short peptides normalised age-related changes in hepatocyte gene expression, reduced oxidative stress markers, and improved mitochondrial function parameters in hepatic tissue.

View on PubMed →
WHAT THE RESEARCH SHOWS
KNOWN
  • Organ-specific hepatocyte chromatin interaction mechanism
  • Anti-fibrotic hepatic effects in preclinical models — reduces stellate cell activation and TGF-β1 signalling
  • 4–6 month Cytomax aftereffect — year-round liver protection from twice-yearly courses
  • Clinical use in liver disease patients with improved enzyme profiles (Khavinson group)
  • Complementary to TUDCA and NAC — different mechanisms, not redundant
?UNCERTAIN
  • ?Independent Western validation of liver enzyme normalisation
  • ?Whether effects differ between healthy and diseased livers in terms of magnitude
  • ?Head-to-head comparison with TUDCA or silymarin on liver enzyme outcomes
  • ?Optimal dosing for different liver conditions — NAFLD vs. chronic hepatitis vs. healthy prevention
  • ?Whether Svetinorm outperforms Livagen (Cytogen) for the hepatic application

Community knowledge

Svetinorm's primary community is users who run significant compound protocols — multiple peptides, other hepatically-processed compounds — and take liver protection seriously. It is also used by anyone with elevated liver enzymes, NAFLD, or a family history of liver disease who wants the organ-level bioregulator layer alongside standard liver-protective agents.

The liver protection stack: Svetinorm + TUDCA + NAC is the most comprehensive liver protection approach — three distinct mechanisms addressing hepatic health simultaneously
Liver enzyme improvement: users tracking ALT/AST report improvement during and after Svetinorm courses; bloodwork is the primary way to assess its effects
Used before and after heavy compound protocols: run a Svetinorm course 1–2 weeks before starting a hepatotoxic protocol, then repeat when ending it
The Livagen comparison: some users alternate Svetinorm (Cytomax) and Livagen injectable (Cytogen) — natural complex every 6 months with synthetic peptide between courses

LIVER PROTECTION STACK

Svetinorm (gene expression) + TUDCA (ER stress / bile acid) + NAC (glutathione / Phase II) = three complementary mechanisms. No single compound covers all three layers.

AI RESEARCHER PREVIEW
I run multiple compound protocols. How do I combine Svetinorm with TUDCA and NAC for comprehensive liver protection?
The three-layer approach covers different mechanisms simultaneously. Svetinorm (gene expression): run a 10-day oral course (2 capsules twice daily) 1-2 weeks before starting your heaviest protocol period, then again when you're ending it — twice yearly minimum. TUDCA 500mg twice daily: run ongoing during any active compound protocol. The ER stress protection and bile acid normalisation are most relevant when the liver is actively processing compounds. NAC 600mg twice daily: ongoing glutathione precursor support. Phase II detoxification directly supports clearance of processed compounds. Timing Svetinorm courses around your protocol calendar is the key decision. If you're running a spring and autumn protocol cycle, time Svetinorm for late March and late September. The 4-6 month aftereffect means your two courses provide hepatoprotective gene expression support year-round. Monitor ALT, AST, GGT at baseline and 6 weeks in. If enzymes remain elevated after the protocol despite this stack, that's a signal to extend the recovery period and repeat the Svetinorm course.
CONTINUE IN THE APP

Open PepperLedger to track your Svetinorm protocol →

Free to join. The Researcher understands liver bioregulator protocols and can help you design comprehensive hepatic protection for your compound stack.

Free to join · No credit card · 23-day Pro trial included

PepperLedger

Educational tool — not medical advice. PepperLedger is a logging and information tool for adults managing their own protocols. It does not prescribe, diagnose, or treat anything. Always work with a qualified healthcare provider for medical decisions.

Educational tool — not medical advice. Svetinorm is not FDA-approved. Consult a hepatologist if you have liver disease before starting. Not a substitute for standard liver care or medication.

© 2026 Realee AI · PepperLedger